Leader'S Club
Leader'S Club은 유가증권 성장 법인과 코스닥 성장 법인을 대상으로 IR(Investor Relations)활동을 지원하는 서비스 입니다.
PRICE(20minute delay)
-
₩ 0
₩ %
-
$
$ %
-
Previous Close
0
-
Open
0
-
High
0
-
Low
0
-
Volume
0
-
Market Cap (T KRW)
0
-
Industry
Etc.
-
CEO
Juergen Koenig
-
Headquarters
15F, Haesung-2-building, 942-10, Daechi-dong, Gang
-
Website
Related Articles
-
Samsung Biologics Reports Second Quarter 2022 Financial Results
Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed on April 20, 2022 Achieved record-high semi-annual revenue exceeding KRW 1 trillion Recorded Q2'22 revenue of KRW 503.7 billion for the company's CDMO business Recorded Q2'22 revenue of KRW 232.8 billion for Samsung Bioepis's biosimilars business Business operations remain stable with expanded base for future growth INCHEON, South Korea, July 27, 2022 /PRNewswire/
-
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Almira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengthen its R&D capability. "We are extremely pleased to welcome Dr. Chabi as Chief Medical and Development Officer. Dr. Chabi will bring invaluable expertise and leadership to ou
-
HanAll Biopharma Reports First Quarter 2021 Financial Results
Q1'21 sales of KRW 27.8 billion increased 26% compared to Q1'20 Q1'21 operating profit of KRW 5.4 billion increased 80% compared to Q1'20 Q1'21 operating margin of 19%, up from 14% in Q1'20 Better-than-expected sales and operating profit are largely due to an increase of R&D revenue including milestone payment SEOUL, South Korea, May 6, 2021 /PRNewswire/ -- HanAll Biopharma (KRX: 009420) (HanAll) announced on the 29th, Apr. that it achieved 27.8 billion won in sales, 5.4 bill
-
Insightful Science Joins Forces with Dotmatics to Form a Leading Cloud-First Scientific R&D Company
- Combined company will generate well over $100 million of ARR and signals a significant transformation in the future of software and data management in research labs. - Enabling over one million scientists to improve research and lab efficiency. - Facilitating rapid data access and exchange between scientists around the world, ultimately giving customers a competitive edge. BISHOP'S STORTFORD, United Kingdom and SAN DIEGO, March 22, 2021 /PRNewswire/ -- Insightful Science, a leading
-
Osong aims to become bio industry hub
Osong is looking to solidify its position as the country’s mecca for biotechnology research with the upcoming Bio Industry Expo Osong Korea 2014.The event, slated to be held in the North Chungcheong Province city, will provide opportunities for corporations in and out of Korea to gather and share business propositions on medical facilities, medicine and aesthetic products. Some 230 leading companies in the field around the globe are expected to take part in the 17-day event from Sept. 26 to Oct.
-
Merck to support Korea’s biopharmaceutical sector
Executive board member Reckmann says biosimilars have great potentialA board member of global chemical and pharmaceutical giant Merck KGaA said Tuesday that the company will continue to show support for Korea’s fast growing biotechnology industry, especially toward a special class of medicines called “biosimilars.”“Korea has built up a country strategy where a clear target is to be one of the leaders in biotechnology products worldwide (through exports of these drugs),” said Bernd Reckmann, a ge
-
Merck Korea opens new R&D laboratory on OLED
Merck Ltd. Korea said on Sunday that its new Application Development Laboratory has gone into operation at the Advanced Technology Center in Poseung, Pyeongtaek in southwestern Gyeonggi Province. The multinational company started the operation after holding an opening ceremony for the laboratory, bu
-
Hanwha, Merck sign license deal on biosimilar drug
Hanwha Chemical Corp., the country’s leading petrochemical firm, said on Monday it has reached a license agreement worth $720 million for its arthritis biosimilar with Merck Sharp & Dohme Research Ltd., a subsidiary of U.S. drugmaker Merck & Co.Under the deal, the two companies plan to develop and commercialize the drug candidate named HD 203 together. Merck secures its sales rights in all countri
-
Artist lights up traditional colors
South Korean artist Lee Kye-song, known as the “painter of light,” is showcasing around 50 oil paintings at his solo exhibition at Insa Art Center in Gwanhun-dong, central Seoul. Lee uses “obangsaek,” or the five traditional Korean colors of white, black, red, blue and yellow, in a very modern way which resembles splashes of LED light. “The paintings on show are very bright, like LED lights. As LE